Medika International

Diabetic Foot

What is diabetic foot?

The diabetic foot, stands out among the most feared complications (20% of diabetic patients will have ulcers on their feet at any time of their life) and it is therefore one of the main causes of physical-motor handicaps. It is known that 50% of major amputations are related to diabetes mellitus and its neurovascular complications, with a high economic and social cost.

Our treatment

Cuba has successfully developed a unique new drug to treat diabetic foot ulcers: Heberprot-P®. It is a lyophilized product, sterile, white color, without preservatives, for parenteral consumption. This product contains recombinant human epidermal growth factor, 75 μg / ampoule.

Benefits of Heberprot-P®

  • Stimulates progressive and continuous granulation and healing
  • Reduces the number of debridement and surgical procedures
  • Reduces the number of recurrences
  • Reduces healing time and, therefore, complications such as gangrene and infection or over-infection, when the wound becomes deeper and more tissue is debrided until amputation
  • Reduces hospital stay costs
  • Increases quality of life and functional recovery of the patient

Our program includes

  • Stimulates progressive and continuous granulation and healing
  • Reduces the number of debridement and surgical procedures
  • Reduces the number of recurrences

The Medika guidance

From the first contacts to the surgery, not to mention the transportation and the accomodation, discover the complete Medika guidance!